Obesity is a significant public health concern in the G7 countries and is growing as an epidemic. The body of evidence highlighting the physical and economic impact of obesity on society is steadily increasing. Despite the disease’s prevalence, few drug treatments are available, especially in Europe and Japan. Compounding this problem is the fact that available treatments do not have desirable risk-benefit profiles at low prices; in addition, few novel agents are in development for obesity. Consequently, there is a huge market opportunity for an antiobesity drug that elicits sustained weight loss and is safe, well tolerated, and affordable. However, with the prevalence of obesity, even if such an agent is developed and approved, payers will likely need to restrict its access to limit the impact on finite healthcare budgets.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.